Landmark trials of medicine, told in a single sentence.
29 oncology trials in 9 topics.
Topics in oncology
Lung cancer
EGFR and ALK TKIs, immunotherapy in (neo)adjuvant and metastatic NSCLC, and immune chemotherapy in SCLC.Breast cancer
HER2-targeted therapy, CDK4/6 inhibition, PARP inhibitors and immunotherapy in early and metastatic disease.Gastrointestinal cancers
Adjuvant FOLFOX, anti-EGFR in RAS-WT mCRC, FOLFIRINOX, immunotherapy in MSI-H and oesophageal/gastric cancers.Genitourinary cancers
Triplet therapy in mHSPC, immune-combination therapy in RCC, ADC-immunotherapy in urothelial and PSMA radioligand therapy.Haematologic malignancies
BCR-ABL TKIs in CML, BTK and BCL-2 inhibition in CLL, anti-CD38 in myeloma, BCL-2/HMA in AML and CD19 CAR-T in lymphoma.Melanoma & skin cancers
BRAF/MEK inhibition, anti-PD-1 monotherapy and combination checkpoint blockade.Gynaecologic cancers
PARP-inhibitor maintenance in BRCA/HRD-positive ovarian cancer and immunotherapy in cervical and endometrial cancer.Head & neck cancer
Anti-EGFR therapy and PD-1 blockade in recurrent/metastatic squamous-cell carcinoma.CNS tumours
The Stupp regimen in newly diagnosed glioblastoma and IDH-targeted therapy in low-grade glioma.
In 17,187 patients with suspected acute myocardial infarction, aspirin plus intravenous streptokinase reduced 5-week vascular mortality compared with placebo.